1/13
08:30 am
bfri
Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth
Low
Report
Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth
1/8
08:45 am
bfri
Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones
Medium
Report
Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones
12/18
08:45 am
bfri
Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio
Medium
Report
Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio
12/4
09:00 am
bfri
Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities
Medium
Report
Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities
12/2
09:06 am
bfri
Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT [Yahoo! Finance]
Low
Report
Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT [Yahoo! Finance]
12/2
08:45 am
bfri
Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT
Low
Report
Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT
11/14
12:15 pm
bfri
Biofrontera (NASDAQ:BFRI) had its "buy" rating reaffirmed by analysts at Benchmark Co..
Medium
Report
Biofrontera (NASDAQ:BFRI) had its "buy" rating reaffirmed by analysts at Benchmark Co..
11/13
11:53 am
bfri
Biofrontera Inc. (BFRI) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Biofrontera Inc. (BFRI) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/13
08:15 am
bfri
Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update
Medium
Report
Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update
11/7
08:00 am
bfri
Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M
High
Report
Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M
11/6
04:01 pm
bfri
Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025
Medium
Report
Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025
10/30
12:25 pm
bfri
Biofrontera (NASDAQ:BFRI) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Biofrontera (NASDAQ:BFRI) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/23
08:45 am
bfri
Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG
Medium
Report
Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG